The relationship between osteoporotic fracture risk and a surrogate: apparent discrepancies between analyses based on individual patient data and summary statistics

被引:7
作者
Barton, I [1 ]
机构
[1] Procter & Gamble Co, Dept Biometr & Stat Sci, Egham TW20 9NW, Surrey, England
关键词
risedronate; fractures; regression analysis; meta-analysis; clinical trial;
D O I
10.1002/pst.123
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is debate within the osteoporosis research community about the relationship between the risk of osteoporotic fracture and the surrogate measures of fracture risk. Meta-regression analyses based on summary data have shown a linear relationship between fracture risk and surrogate measures, whereas analyses based oil individual patient data (IPD) have shown a nonlinear relationship. We investigated the association between changes in a surrogate measure of fracture incidence, in this case a bone turnover marker for resorption assessed in the three risedronate phase III clinical programmes, and incident osteoporosis-related fracture risk using regression models based on patient-level and trial-level information. The relationship between osteoporosis-related fracture risk and changes in bone resorption was different when analysed on the basis of IPD than when analysed on the basis of a meta-analytic approach (i.e., meta-regression) using summary data (e.g., treatment effect based oil treatment group estimates). This inconsistency in our findings was consistent with those in the published literature. Meta-regression based on summary statistics at the trial level is not expected to reflect causal relationships between a clinical outcome and surrogate measures. Analyses based oil IPD make possible a more comprehensive analysis since all relevant data on a patient level are available. Copyright (C) 2004 John Wiley Sons Ltd.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 29 条
  • [1] [Anonymous], 1997, AM J MED
  • [2] Risk of mortality following clinical fractures
    Cauley, JA
    Thompson, DE
    Ensrud, KC
    Scott, JC
    Black, D
    [J]. OSTEOPOROSIS INTERNATIONAL, 2000, 11 (07) : 556 - 561
  • [3] Cooper C, 1999, OSTEOPOROSIS INT, V9, P2
  • [4] Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs
    Cummings, SR
    Karpf, DB
    Harris, F
    Genant, HK
    Ensrud, K
    LaCroix, AZ
    Black, DM
    [J]. AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04) : 281 - 289
  • [5] Treatment of postmenopausal osteoporosis
    Delmas, PD
    [J]. LANCET, 2002, 359 (9322) : 2018 - 2026
  • [6] Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
    Eastell, R
    Barton, I
    Hannon, RA
    Chines, A
    Garnero, P
    Delmas, PD
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) : 1051 - 1056
  • [7] Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?
    Eastell, R
    Reid, DM
    Compston, J
    Cooper, C
    Fogelman, I
    Francis, RM
    Hay, SM
    Hosking, DJ
    Purdie, DW
    Ralston, SH
    Reeve, J
    Russell, RGG
    Stevenson, JC
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2001, 94 (11) : 575 - 597
  • [8] *EUR AG EV MED PRO, 2001, EV MED HUM US NOT GU
  • [9] Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial
    Fogelman, I
    Ribot, C
    Smith, R
    Ethgen, D
    Sod, E
    Reginster, JY
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) : 1895 - 1900
  • [10] Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial
    Harris, ST
    Watts, NB
    Genant, HK
    McKeever, CD
    Hangartner, T
    Keller, M
    Chesnut, CH
    Brown, J
    Eriksen, EF
    Hoseyni, MS
    Axelrod, DW
    Miller, PD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14): : 1344 - 1352